In connection with the execution of the merger agreement, certain stockholders of 2seventy bio owning approximately 5.3% of the outstanding shares of 2seventy bio’s common stock have entered into ...
Enrollment in MAD portion of the trial continues with higher doses being evaluated OXFORDSHIRE, UK & CONSHOHOCKEN, PA & GAITHERSBURG, MD, USA I March 10, 2025 I Immunocore Holdings plc (Nasdaq: IMCR) ...
BOTHELL, WA, USA I March 10, 2025 I Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted ...
EMERYVILLE, CA, USA I March 10, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
CHENGDU, China I March 10, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's ...
BAGSVAERD, Denmark I March 10, 2025 I Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme.
AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment -- ...
COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...
About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...
LONDON, UK & CHICAGO, IL, USA I March 05, 2025 I Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm ...
PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback